Title: Optimal Iron Management in Patients Receiving Erythropoietin Therapy
Abstract: Seminars in DialysisVolume 11, Issue 1 p. 10-13 Optimal Iron Management in Patients Receiving Erythropoietin Therapy Iain C. Macdougall, Corresponding Author Iain C. Macdougall Department of Renal Medicine, King's College Hospital, London, United KingdomAddress correspondence to: Dr Iain C Macdougall, Consultant Nephrologist, Department of Renal Medicine, King's College Hospital (Dulwich), East Dulwich Grove, London SE22 8PT, United KingdomSearch for more papers by this author Iain C. Macdougall, Corresponding Author Iain C. Macdougall Department of Renal Medicine, King's College Hospital, London, United KingdomAddress correspondence to: Dr Iain C Macdougall, Consultant Nephrologist, Department of Renal Medicine, King's College Hospital (Dulwich), East Dulwich Grove, London SE22 8PT, United KingdomSearch for more papers by this author First published: 01 October 2007 https://doi.org/10.1111/j.1525-139X.1998.tb00199.xCitations: 3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Horl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during r-huEPO therapy—a consensus report. Nephrol Dial Transplant 11: 246–250, 1996. 2 Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW: USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76: 160–165, 1989. 3 Tsobanelis T, Hoppe D, Scigalla P, Grutzmacher P. Optimierte Behandlung der renalen Anamie mit kombinierter intravenoser Eisen- und Ultra-low-dose-Erythropoietin-Substitution. (abstract) Nieren-Hochdruckkrankheiten 20: 454, 1991. 4 Anastassiades EG, Howarth D, Howarth J, Shanks D, Waters HM, Hyde K, Geary CG, Yin JAL, Gokal R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8: 846–853, 1993. 5 Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, Mattern W, Schreiber M, Swartz R, Van Stone J, Watson A, Zimmerman S: Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5: 1517–1529, 1995. 6 Faller B, Slingeneyer A, Waller M, Michel C, Grutzmacher P, Muller HP, Barany P, Grabensee B, Issad B, Schmitt H, Meisl F: Daily subcutaneous administration of recombinant human erythropoietin in peritoneal dialysis patients: A European dose-response study. Clin Nephrol 40: 168–175, 1993. 7 Barany P, Clyne N, Hylander B, Johansson A-C, Simonsen O, Larsson R, Frisenette-Fich C, Svensson B, Helmers C: Subcutaneous epoetin beta in renal anemia: An open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 15: 54–60, 1995. 8 Macdougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opinion Nephrol Hypertension 3: 620–625, 1994. 9 Cavill I: Diagnostic methods, in Disorders of Iron Metabolism. Clin Haematol II: 259–275, 1982. 10 Worwood M: Ferritin. Blood Rev 4: 259–269, 1990. 11 Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78, 1987. 12 Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. Br Med J 304: 225–226, 1992. 13 Crosby WH: The rationale for treating iron deficiency. Arch Intern Med 144: 471–472, 1984. 14 Eschbach JW, Cook JD, Finch CA: Iron absorption in chronic renal disease. Clin Sci 38: 191–196, 1970. 15 Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO: Iron metabolism in haemodialysis patients. Q J Med 48: 369–391, 1979. 16 Kooistra MP, Van Es A, Struyvenberg A, Marx JJM: Low iron absorption in erythropoietin-treated hemodialysis patients. J Am Soc Nephrol 6: 543, 1995. 17 Bonnar J, Goldberg A, Smith JA: Do pregnant women take their iron Lancet i: 457–458, 1969. 18 Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299: 157–158, 1989. 19 Wingard RL, Parker RA, Ismail N, Hakim RA: Efficacy of oral iron therapy in patients receiving rhEPO. Am J Kidney Dis 25: 433–439, 1995. 20 Schaefer RM, Schaefer L: The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 23: 83–88, 1995. 21 Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694–1699, 1996. 22 Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10: 2070–2076, 1995. 23 Rosenlof K, Kivivuori SM, Gronhagen-Riska C, Teppo AM, Slimes MA: Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 43: 249–255, 1995. 24 Zanen AL, Adriaansen HJ, Van Bommel EFH, Posthuma R, De Jong GMT: 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 11: 820–824, 1996. 25 Schaefer RM, Schaefer L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients. Erythropoiesis 3: 71–75, 1992. 26 Nyvad O, Danielsen H, Madsen S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet 344: 1305–1306, 1994. 27 Sepandj F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11: 319–322, 1996. 28 Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41–46, 1995. 29 Ascherio A, Willet WC: Are body iron stores related to the risk of coronary heart disease N Engl J Med 330: 1152–1153, 1994. 30 Sussman HH: Iron in cancer. Pathobiology 60: 2–9, 1992. 31 Weinberg ED: Iron withholding: A defense against infection and neoplasia. Physiol Rev 64: 65–102, 1984. Citing Literature Volume11, Issue1January 1998Pages 10-13 ReferencesRelatedInformation
Publication Year: 1998
Publication Date: 1998-01-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 5
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot